What question did this study set out to answer?

To evaluate the safety and immunogenicity of two-dose regimens of 50 µg and 100 µg mRNA-1273 SARS-CoV-2 vaccine in adult participants.

February 9, 2021VaccineOpen Access

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

View Full Paper

Ask AI

Bookmark

Why the study?

Does mRNA-1273 given as a 2 dose-regimen improve immune responses to SARS-CoV-2 in participants 18 years and older?

Population

Participants 18 years and older

Comparison

50 µg mRNA-1273 vs 100 µg mRNA-1273 given as a 2 dose-regimen

Design

Randomized controlled phase 2 trial

Authors

LCLaurence ChuNIHR Clinical Research Network RMRoderick McPheeModerna Therapeutics (United States)WHWenmei HuangModerna Therapeutics (United States)

Discussion

Member takes

Implication

Supports mRNA-1273 in adults; extends equivocal data from 2 prior small studies.

Key Points

To evaluate the safety and immunogenicity of two-dose regimens of 50 µg and 100 µg mRNA-1273 SARS-CoV-2 vaccine in adult participants.
Randomized controlled phase 2 clinical trial (ClinicalTrials.gov: NCT04405076).
Evaluated two-dose regimens of 50 µg and 100 µg mRNA-1273 in participants aged 18 years and older.
Vaccination with mRNA-1273 generated significant immune responses to SARS-CoV-2 in adults 18 years and older.
An acceptable safety profile was confirmed for both the 50 µg and 100 µg two-dose vaccine regimens.

Structured PICO

Does mRNA-1273 given as a 2 dose-regimen improve immune responses to SARS-CoV-2 in participants 18 years and older?

Population

participants 18 years and older

Intervention

mRNA-1273 50 and 100 µg given as a 2 dose-regimen

Outcome

safety and immunogenicitysafety

The mRNA-1273 vaccine at 50 and 100 µg doses is safe and immunogenic in adults.

Cite This Study

Chu et al. (2021) studied this question.

synapsesocial.com/papers/69d8fd19a5ecc596b5d18f65 https://doi.org/10.1016/j.vaccine.2021.02.007

View Full Paper

Ask AI

Bookmark

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider